Loading clinical trials...
Loading clinical trials...
Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take t...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sanofi
NCT07571161 · Alzheimer Disease
NCT06847321 · Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
NCT06937229 · Alzheimer Disease, Agitation
NCT07633470 · Alzheimer Disease
NCT04579120 · Alzheimer Disease
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey
Sanofi-Aventis Administrative Office
Paris
Sanofi-Aventis Administrative Office
Milan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions